These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30334899)

  • 1. Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
    Milner TD; Ronghe M; Shaikh MG; MacGregor FB; Reed N
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):e329-e332. PubMed ID: 30334899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.
    Narayanan VK; Ronghe M; MacGregor FB; Bradshaw N; Davidson R; Welbury R; Reed N; Shaikh MG
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):155-7. PubMed ID: 26479990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].
    Segura D; Dupuis C; Chabre O; Piolat C; Durand C; Plantaz D
    Arch Pediatr; 2016 Aug; 23(8):840-4. PubMed ID: 27345554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
    Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictive Value of
    Werner RA; Schmid JS; Higuchi T; Javadi MS; Rowe SP; Märkl B; Aulmann C; Fassnacht M; Kroiss M; Reiners C; Buck AK; Kreissl MC; Lapa C
    J Nucl Med; 2018 May; 59(5):756-761. PubMed ID: 29025983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.
    Thomas N; Glod J; Derse-Anthony C; Baple EL; Osborne N; Sturley R; Vaidya B; Newbold K; Brooke A
    Clin Endocrinol (Oxf); 2018 May; 88(5):754-756. PubMed ID: 29457255
    [No Abstract]   [Full Text] [Related]  

  • 11. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
    Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
    Werner RA; Schmid JS; Muegge DO; Lückerath K; Higuchi T; Hänscheid H; Grelle I; Reiners C; Herrmann K; Buck AK; Lapa C
    Medicine (Baltimore); 2015 Nov; 94(45):e2016. PubMed ID: 26559299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
    Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
    Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
    Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma.
    Kothari R; Kreimer S; Nadel H; Seeley H; Hartman G; Meister KD
    JCO Precis Oncol; 2024 Jan; 8():e2300257. PubMed ID: 38207224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vandetanib for the treatment of medullary thyroid carcinoma.
    Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
    Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
    Demir Gündoğan B; Sağcan F; Tuğ Bozdoğan S; Balcı Y; Tuncel Daloğlu F; Çağlar Çıtak E
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):342-346. PubMed ID: 32702947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
    Hadoux J; Schlumberger M
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volumetric and texture analysis of pretherapeutic
    Werner RA; Bundschuh RA; Higuchi T; Javadi MS; Rowe SP; Zsótér N; Kroiss M; Fassnacht M; Buck AK; Kreissl MC; Lapa C
    Endocrine; 2019 Feb; 63(2):293-300. PubMed ID: 30206772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.